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histopathological types. On immunostaining expression pattern of CK 
in large cell carcinoma was similar to that of adenocarcinoma.
Conclusion: The investigations of CK expression give us additional 
information concerning histopathological differentiation of primary 
lung cancer. Though more investigations are needed, there is a strong 
possibility that classiﬁcation based upon proteomic analysis, as well 
as morphological features, may reﬂect the biological characteristics of 
tumor cells.
P2-060 BSTB: Others Posters, Tue, Sept 4 
Altered iron metabolism, inflammation, transferrin receptors and 
ferritin expression in lung cancer
Kukulj, Suzana 
Clinical Hospital For Lung Diseases Jordanovac, Zagreb, Croatia
Introduction: Alterations in whole-body iron metabolism are known 
to occur in patients with cancer. Iron could participate in carcinogenesis 
and overabundance of iron is associated with increased risk of neopla-
sia at the site of metal deposition. 
Aim: The relationship between the iron status and survival of lung 
cancer patients and the expression of transferrin receptors 1 (TfR1) and 
ferritin in tumor tissue, tumor stroma and normal lung were studied. 
Patients and Methods: These ﬁndings were correlated with tumor 
type and clinical outcome in 111 male patients. Iron metabolism and 
inﬂammation parameters were determined by automated laboratory 
measurements at the time of diagnosis. TfR1 and ferritin expression 
were determined by immuno-histochemical methods on cancer tissue, 
tumor stroma and on the surrounding normal lung tissue. 
Results: More than ﬁfty percentages of patients survived less than 12 
months. At the time of diagnosis approximately a half of the patients 
had mild anemia of chronic disease and signiﬁcantly elevated serum 
ferritin. Nonspeciﬁc laboratory markers of inﬂammation were present. 
Tumor tissue expressed much more TfR1 and ferritin than the tumor 
stroma and normal lung tissue. The expression of TfR1 and the ferritin 
content in tumor tissue depended on the carcinoma type. TfR1 and the 
ferritin content in tumor tissue did not show correlation with systemic 
parameters of most of iron metabolism parameters. Strong ferritin ex-
pression in tumor tissue correlates only with lower transferin saturation.
Conclusion: Higher expression of ferritin in tumor tissue is not the re-
sults of higher body iron accumulation. Elevated serum ferritin in lung 
cancer patients is results of inﬂammation and oxidative stress rather 
than body iron overload. 
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Introduction: For some years, NSE has been known as a marker of 
choice for small cell lung cancer. However, its diagnostic sensitivity 
and speciﬁcity are not completly satisfactory, due to relatively high 
false negative rate in SCLC patients with limited disease and false posi-
tive rate in patients with non-malignant lung disease and non-small cell 
lung cancer. Recently, the usefulness of pro-gastrin-releasing peptide 
(ProGRP) as a tumor marker for SCLC has been investigated. Although 
the diagnostic sensitivity and speciﬁcity of ProGRP was found to be 
higher than serum NSE, only small number of data concern its utility 
in disease therapy monitoring and its value in prediction of response 
to treatment. The aim of the study was the evalutation of ProGRP and 
NSE levels at the time of diagnosis and during chemo- and radiothera-
py of SCLC patients with limited disease in respect to their prognosis.
Material and Methods: Studies of NSE and ProGRP were performed 
in a group of 52 SCLC-LD. Patients with SCLC with limited disease 
were treated simultaneously with chemo and radiotherapy. All of them 
also received prophylactic cranial irradiation between fourth and ﬁfth 
course of chemotherapy. The increment ratio of tumor markers was 
calculated as serum concentration divided by the cut off, for assessment 
of prognostic value of these markers.
Results: ROC curve analysis conﬁrmed that ProGRP was a better than 
NSE tumor marker for diagnostics of SCLC-LD patients ( Area under 
curves ROC: 0.935 vs. 0.789, p = 0.000). 
There were observed signiﬁcant differences in the frequency of 
elevated NSE and ProGRP levels before each course of chemotherapy 
and 3 months after its ﬁnishing, respectively:1st 57.6% vs. 78.8%, 2nd 
5.8% vs. 67.3%, 3th 0% vs. 36.5%, 4th 1.9% vs. 21.2%, in restaging 
6.7% vs. 15.7%. Changes in NSE levels during therapy were more in-
tensive than for ProGRP what was reﬂected in tumor markers half-life 
(NSE: 4.6 - 11 days; ProGRP: 19-28 days) as well as in the frequency 
of increment of tumor markers ratio values. Patients with tumor marker 
levels 2 times exceeding NSE cut off and 12.5-times ProGRP cut off 
before treatment, and those with NSE and ProGRP having these ratio 
values higher than 0.4 and 0.65 during restaging 3 months after ﬁnish-
ing therapy has shown worse prognosis. 
Multivariate analysis conﬁrmed that independent prognostic factors in 
SCLC with limited disease were: NSE level exceeding 2-times cut off 
value before treatment as well as NSE threshold 0.4 cut off and 0.65 
ProGRP cut off value 3 months after therapy.
Conclusions: 
1 Changes of ProGRP during combined therapy of SCLC-LD seem to 
be more adequate to actual clinical status of patients than NSE
2. NSE before treatment is a better than ProGRP prognostic factor in 
SCLC-LD patients however after ﬁnishing therapy both markers 
have similar predictive value
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Background: Low levels of circulating cell-free DNA are present in 
normal individuals. In cancer patients, much higher levels of circulating 
DNA are found. Importantly, circulating DNA in lung cancer patients 
demonstrates genetic alterations typical of the tumour, leading to interest 
in plasma and serum DNA for early clinical diagnosis, prognosis and 
disease monitoring. There is considerable variation among studies in the 
reported levels of circulating DNA and its characteristics, which may be 
attributable to differences in selection of the patient and control groups, 
and the methods used for DNA extraction and estimation of circulating 
DNA concentrations. Here, we compare the efﬁciency of different meth-
ods for extracting low-level circulating DNA from blood samples.
